A study to find the optimal dose for vitamin K supplementation in patients being treated with vitamin K antagonists to create an anti-coagulation effect

Not Applicable

Completed

• Conditions: Anti-coagulant treatment; Haematological Disorders; Other coagulation defects

• Registration Number: ISRCTN37109430
• Lead Sponsor: etherlands Heart Foundation (Nederlandse Hartstichting) (The Netherlands)

Brief Summary

2011 results in https://pubmed.ncbi.nlm.nih.gov/21193422/ (added 23/10/2020)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2008-03-31
• Study Completion: 2009-03-31
• Last Update Posted: 2 November 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 400

Inclusion Criteria

1. Start treatment with vitamin K antagonists less then four weeks before inclusion
2. Treatment with vitamin K antagonists for a minimal period of six months, with the therapeutic range of International normalised ratio (INR) between 2.5 anf 3.5
3. Aged between 18 and 85 years, either sex
4. Measurement of the INR by the Thrombosis Service Leiden
5. Informed consent

Exclusion Criteria

1. Treatment for liver failure
2. Dialysis, both peritoneal and haemodialysys
3. Pregnancy, or wish to get pregnant; lactational period
4. Known to have a chronic condition with a life expectancy of less than six months
5. An expected interruption of treatment with oral anti-coagulants for one week or longer
6. Participation in the self-management protocol

Study & Design

• Study Type: Interventional
• Study Design: Not specified